Small and specialized vaccine R & D team brings opportunities for capital

Until the exposure of 13 price pneumonia combined vaccine in 2011, the whole team of minhai biology didn't make a penny for the company, and the supporter behind it is Shenzhen Kangtai Biological Products Co., Ltd., the largest hepatitis B vaccine manufacturer in China at present With the continuous activity of biological products companies in the capital market, vaccine R & D enterprises are gradually exposed to the public In fact, both bright listed companies and silent non listed companies are actively seizing the core team of R & D As the insiders of Zhongsheng group said, "a vaccine is highly mysterious in the research stage When it is known to the outside world, it often has entered the clinical stage Because in addition to competing with each other, the vaccine industry even involves national security secrets " Minhai biology, a non listed company with accumulated R & D achievements, ranks first among the batch issuing teams of CIIS Minhai biology naturally holds several key projects In the past two years, 13 price pneumonia combined vaccine, which has been snatched by Listed Companies in succession, was first launched by minhai biology and first entered the clinical trial stage According to the data of the Institute, the acceptance number of 13 valent pneumonia combined vaccine of Beijing minhai biological Co., Ltd is cxsl0900041, which entered the review process after application on March 12, 2010 Watson bio entered the application only in 2011, and Lanzhou Institute delayed to 2012 In terms of application time, minhai biology is nearly two years earlier than several major research teams Of course, what minhai biology has is not only these items This year, whether there is cell-free Haemophilus influenzae B combined vaccine, cell-free Haemophilus influenzae B combined vaccine and measles rubella combined live attenuated vaccine have attracted the attention of the industry Haemophilus influenzae type B acellularis vaccine is a kind of vaccine which can prevent pertussis, diphtheria, tetanus and diseases caused by Haemophilus influenzae type B at the same time It is the first time that our country has successfully developed and put on the market, breaking the monopoly of foreign technology If we find minhai creatures, we will naturally find their most important core figure, Wei Wenjin As the founder and leader of the company's R & D projects, Wei Wenjin has the working background of the Xinjiang Military Region anti epidemic team and the academic background of the Academy of Military Medical Sciences He has experienced many ups and downs with minhai biology In fact, the company has not listed a new product for seven years since it joined minhai biology as the head of R & D department in 2004 Although the research and development of 20 vaccine varieties has been carried out, which can prevent 19 diseases, 19 of them have applied for national invention patents, and three have obtained patent certificates, but he confessed that "it is supported by the boss" That is to say, the whole team didn't make any money for the company until the exposure of 13 price pneumonia combined vaccine in 2011, and the supporter behind it was Shenzhen Kangtai Biological Products Co., Ltd Maybe many people think it's a little-known small company In fact, it's the largest hepatitis B vaccine manufacturer in China, with an annual production capacity of more than 100 million Its products cover 31 provinces, cities and autonomous regions, with a market share of more than 50% It's also an entrepreneurial team that supports people and marine products In the past seven years, Kangtai biology has spent 600 million yuan The team has expanded from seven members to more than 70 today Of course, today's minhai biology has passed the most difficult time The latest vaccine project has been GMP certified and successfully listed, with an annual sales value of more than 400 million yuan After Kangtai biology has this powerful subsidiary, it has been thinking about the opportunity to go public And the company has indeed completed the pre IPO guidance work, but it has not yet knocked on this door But the ownership structure of the company has changed quietly Several former major shareholders such as ANGLI of Jiaotong University, Shanghai Huarui Investment Co., Ltd and Guotou hi tech have all sold their shares, while Du Weimin, the current boss, bought 76% of the equity of Kangtai biology through Shenzhen ruiyuanda Investment Co., Ltd In fact, he was also an important decision maker of Jiangsu Yanshen Biotechnology Co., Ltd However, at present, Kangtai biology still does not see the trend of listing Of course, this does not affect the continued efforts of the people and sea creatures In April this year, minhai biology company signed a contract with who and intravac of the Netherlands to introduce a complete set of production technology and quality management system of SIPV (polio inactivated vaccine) unique to intravac The vaccine produced by minhai biology will be purchased by who and enter the international market The reason why minhai biology was selected by Finnish companies is precisely because of the international cooperation strength of minhai biology The company once cooperated with Merck in hepatitis B vaccine, Pasteur in rabies vaccine, the National Institutes of health in the United States in five price round vaccine, and the path foundation in vaccine adjuvant It is reported that the cooperation has also received strong support from the Bill Gates Melinda foundation and the international tuberculosis vaccine Association (aeras) The hepatitis B vaccine team, as Zhongsheng group learned in an interview with financial weekly, has long been wearing the hat of "big country of hepatitis B" In China's statutory infectious disease reporting system, the reported cases of hepatitis B have ranked the first among all infectious diseases for many years, accounting for about one third However, the carrying rate of HBsAg was 7.18% in the population aged 1-59 years The research and development of hepatitis B vaccine started in the 1980s, and implemented the strategy of priority vaccination for children Over the past 30 years, many excellent R & D teams have been bred, and they continue to innovate diligently on this road, gradually shifting their vision from preventive vaccines to therapeutic vaccines Recently, Baiyunshan is the most popular one in this field On March 13, 2014, Baiyunshan released the notice of phase IIB clinical trial of therapeutic double plasmid HBV DNA vaccine, saying: from the whole clinical process and results, the therapeutic double plasmid HBV DNA vaccine has good safety and tolerance, good compliance of the subjects, and low shedding rate However, the R & D team of this project is not entirely from Baiyunshan It was first established by the 458 Hospital of the PLA After 2000, it began to cooperate with Guangyao group In 2006, he got the approval of clinical research and entered the second phase B clinical trial in April 2011 Experts from the R & D team said that phase III clinical trials will be launched as soon as the second half of next year If phase III clinical trials are successful, the vaccine is expected to be on the market within two to three years Up to now, 40-50 million yuan has been invested in the project, and the whole clinical research is expected to cost about 100 million yuan If we dig deep into the whole R & D team, we will find that the project is completed by Chen Guangming, a key figure, in cooperation with Baidi biomedical Co., Ltd., a subsidiary of Guangyao group Chen Guangming is the deputy director and chief pharmacist of liver disease center of Guangzhou Air Force hospital In terms of the success rate of global new drug research and development, the clinical failure rate of phase I is about 80%, that of phase II is about 50% ~ 60%, and that of phase III is about 30% The later the risk rate is lower The phase II clinical trial of Baiyunshan therapeutic hepatitis B vaccine has proved its safety and effectiveness, indicating that there is a certain foundation, and there is great hope for the phase III clinical success Another therapeutic hepatitis B vaccine team is from Fudan Yueda Biotechnology Co., Ltd Although the company itself is extremely low-key, its R & D core is Wen Yumei, an important soul figure in the vaccine industry And the project's product, hexico vaccine, has also been responding to the industry's mixed opinions Zeke was developed by Zhao Jia, academician of the Key Laboratory of medical molecular virology, Medical College of Fudan University and Beijing Institute of biological products The HBsAg antigen and HBIG antibody were mixed in a ratio of 6 to 3 The adjuvant is the same as the common vaccine, which uses aluminum hydroxide, that is, the conformity of the vaccine HBIG, belonging to the protein vaccine At present, the vaccine has completed the third clinical phase, and applied for a new drug certificate, but it has not been asked about the market But some doubters said that it had no effect on the mutated virus, and could not cure hepatitis B, and could not completely kill the virus, there was a situation of rebound when the drug was stopped Therefore, in the future, it will be used to deal with the patients who are not suitable for interferon treatment, have large side effects, liver dysfunction, the patients who produce virus mutants that are resistant to nucleoside drugs, and some people who fail to immunize with preventive vaccines Behind Fudan Yueda, Jiangsu Yueda invested and established, and cooperated with Fudan University to inject 500 million yuan Yueda investment in A-share listing involves a wide range of fields, including machinery, manufacturing and energy However, Fudan Yueda has not been included in his main business income So far, vaccine research and development has not brought real performance returns to listed companies The last therapeutic hepatitis B vaccine team to enter the third phase of clinical research is headed by Wu Yuzhang of Chongqing polypeptide Pharmaceutical Engineering Technology Research Center, Institute of immunology of the Third Military Medical University The R & D company is called Jiachen biology, and Wu Yuzhang owns 5% of the company The hepatitis B vaccine developed by the team is called TCB - therapeutic hepatitis B synthetic peptide vaccine By imitating some peptide chains of hepatitis B antigen and inducing cells to produce antibodies, it belongs to artificial synthesis and computer-aided design of peptide segments Unlike traditional vaccines, which rely on natural proteins, synthetic peptide vaccines use synthetic and synthetic peptide compounds At present, the vaccine has completed the IIb clinical stage Maybe the name of Jiachen biology is unknown, but the Chongqing beer that invests in it should be known to all In the process of promoting the development of hepatitis B vaccine, Chongqing beer also set off several waves of speculation in concept stocks, but unfortunately, the news that a clinical trial failed led to a significant decline in Chongqing beer "Clinical failure doesn't necessarily mean lag At present, Jiachen biology is still a very strong player in the third phase clinical hepatitis B therapeutic vaccine Even if the market is late in the future, there are still differences in product categories and market space This is the difference between preventive and therapeutic vaccines " An insider from the biological products industry told reporters "The product difference of prophylactic vaccine is very small, once taken by a certain enterprise first, the latter will be much inferior." The HIV vaccine team is clustered in all the vaccine listed companies, and HIV is undoubtedly the permanent hot spot But as a cutting-edge project in the field of therapeutic vaccines, so far no one has been able to get a say in this field Reporters according to different types of vaccines do the relevant combing, collected the current more valuable HIV research and development team First of all, DNA Tiantan vaccinia conformable HIV vaccine was set up by China Center for disease prevention and Beijing Institute of biological products Shao Yiming, the core figure of the team, is the chief expert of China STD AIDS prevention and control center, the president of China AIDS vaccine alliance, the director of AIDS research center of Nankai University, and the new academician of American Academy of microbiology At present, the phase II vaccine has also been produced, which has been approved by the State Drug Administration Now, the phase II clinical trial plan is being submitted In the next five years, the vaccine of the completed phase I clinical trial will be pushed into phase II immediately, so that it can enter phase III earlier Strive to launch HIV vaccine with independent intellectual property rights in China in the next 10 years Tiantan biology is the main listed company of the project, Beijing Institute of biological products is its fourth largest shareholder, while China CDC